By Doug Macron

Miragen Therapeutics this week announced that it has partnered three preclinical microRNA drug programs in cardiovascular disease, including its two lead efforts, with France's Les Laboratoires Servier in a deal valued at $45 million over three years.

The transaction gives Servier the rights to the drugs in all territories outside of the US and Japan, and could be worth up to $1 billion to Miragen if all clinical and commercial milestones are met.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.